 |
20% to 40%
of women over 35 have uterine fibroids |
 |
African-American women have a three to five times
greater risk for developing UF than Caucasian women |
 |
ExAblate
is a Magnetic Resonance guided Focused Ultrasound
system which uses a magnetic resonance imaging (MRI)
scanner to identify tissues in the body and plan the
treatment. During the procedure, delivery of Focused
Ultrasound energy is guided and controlled using MR
thermal imaging. |
 |
Works with
the GE 1.5
Tesla MRI system |
 |
Awarded
the CE Mark and ISO 9001 certification in 2002 |
 |
2004 grand
prize winner of
European Union’s IST award for innovation and
potential to
benefit mankind. |
|
 |
Non-invasive, no incision required, no anesthesia |
 |
Low rate
of complications |
 |
Return to
normal activity within one to two days |
 |
Outpatient
procedure – no hospital stay |
 |
The uterus
is preserved |
 |
Women of
child-bearing age
have the option of bearing
children in the future |
|
 |
MR
image allows physician to locate diseased tissue or
tumor |
 |
Ultrasound energy is focused to a small volume
within the
tumor |
 |
Heat
of intense ultrasound waves destroys tissue |
 |
Process is repeated as many times as necessary until
tumor is destroyed |
 |
Body
disposes of destroyed tissue as part of normal
function |
|
 |
In
October 2004, the FDA approved the ExAblate system
for treatment of symptomatic uterine fibroids. The
FDA approval followed regulatory approvals in Europe
in 2002. The system is also in use in
Japan. |
|
 |
Currently,
ExAblate® 2000 has a CPT 3 code. Now that the
procedure is FDA approved, MRI & Imaging of Georgia
is
working to have the procedure covered by insurance.
Until then, we will work with patients to
create an affordable financing plan. |
|